Get the Stockscreener App
2.26
5.83%
-0.14
After Hours:
2.27
0.01
+0.44%
Immunitybio Inc stock is traded at $2.26, with a volume of 8.99M.
It is down -5.83% in the last 24 hours and down -11.02% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
8.99M
Relative Volume:
0.94
Market Cap:
$2.14B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.3299
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-15.04%
1M Performance:
-11.02%
6M Performance:
-11.02%
1Y Performance:
-57.20%
1-Day Range:
$2.25
$2.40
1-Week Range:
$2.25
$2.66
52-Week Range:
$1.83
$5.88
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.26 | 2.36B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
What moving averages say about ImmunityBio Inc.Market Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Will ImmunityBio Inc. stock continue upward momentum2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Why ImmunityBio Inc. (26CA) stock stays undervaluedVolume Spike & Pattern Based Trade Signal System - newser.com
Tick level data insight on ImmunityBio Inc. volatilityIPO Watch & Technical Entry and Exit Tips - newser.com
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickWeekly Market Report & Daily Technical Stock Forecast Reports - newser.com
Will ImmunityBio Inc. (26CA) stock justify high valuationExit Point & Verified High Yield Trade Plans - newser.com
How ImmunityBio Inc. (26CA) stock responds to bond market2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Is ImmunityBio Inc. stock a buy on dipsQuarterly Portfolio Report & Low Volatility Stock Recommendations - newser.com
ImmunityBio Inc. recovery potential after sell offMarket Sentiment Report & Community Verified Trade Alerts - newser.com
ImmunityBio Inc Stock Analysis and ForecastStock Watchlist Updates & Small Investment Growth Tips - earlytimes.in
Why ImmunityBio Inc. (26CA) stock benefits from AI revolutionMarket Growth Report & Community Consensus Stock Picks - newser.com
How ImmunityBio Inc. (26CA) stock compares with tech leadersQuarterly Investment Review & Daily Growth Stock Tips - newser.com
ImmunityBio, Inc. (IBRX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Applying big data sentiment scoring on ImmunityBio Inc.Bear Alert & Safe Capital Growth Tips - newser.com
ImmunityBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why retail investors favor ImmunityBio Inc. stock2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
Can machine learning forecast ImmunityBio Inc. recoveryWatch List & High Accuracy Swing Entry Alerts - newser.com
What drives ImmunityBio Inc 26CA stock priceIPO Market Watch & Low Risk Capital Appreciation - earlytimes.in
How hedge fund analytics apply to ImmunityBio Inc. stockPortfolio Update Summary & Reliable Entry Point Trade Alerts - newser.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):